Pharmaceuticals which alter CB1 activation and 2-AG metabolism may be useful treatment options for specific ASD symptoms linked to stress and anxiety, however, the consequences of endocannabinoid manipulation during brain development are unclear and may have unintended results. The gene discussed is CNR1; the disease is Anxiety.